Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology-Reference-Cited by-同舟云学术

Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

Published:2023-08-16 Issue:10 Volume:62 Page:1333-1364
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

van der Kleij Maud B. A.^ORCID,Guchelaar Niels A. D.^ORCID,Mathijssen Ron H. J.^ORCID,Versluis Jurjen^ORCID,Huitema Alwin D. R.^ORCID,Koolen Stijn L. W.^ORCID,Steeghs Neeltje^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40262-023-01293-9.pdf

Reference245 articles.

1. Yu H, Steeghs N, Nijenhuis CM, Schellens JH, Beijnen JH, Huitema AD. Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets. Clin Pharmacokinet. 2014;53(4):305–25.

2. Hussaarts K, Veerman GDM, Jansman FGA, van Gelder T, Mathijssen RHJ, van Leeuwen RWF. Clinically relevant drug interactions with multikinase inhibitors: a review. Ther Adv Med Oncol. 2019;11:1758835918818347.

3. Mathijssen RH, Sparreboom A, Verweij J. Determining the optimal dose in the development of anticancer agents. Nat Rev Clin Oncol. 2014;11(5):272–81.

4. Veerman GDM, Hussaarts K, Jansman FGA, Koolen SWL, van Leeuwen RWF, Mathijssen RHJ. Clinical implications of food-drug interactions with small-molecule kinase inhibitors. Lancet Oncol. 2020;21(5):e265–79.

5. Verheijen RB, Yu H, Schellens JHM, Beijnen JH, Steeghs N, Huitema ADR. Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology. Clin Pharmacol Ther. 2017;102(5):765–76.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Melt-blown polypropylene nonwoven as an efficient and eco-economic sorbent for pipette tip micro-solid phase extraction for the determination of tyrosine kinase inhibitors;Analytica Chimica Acta;2024-11

2. Development and validation of an ultra‐performance liquid chromatography–tandem mass spectrometry method to quantify the small molecule inhibitors adagrasib, alectinib, brigatinib, capmatinib, crizotinib, lorlatinib, selpercatinib, and sotorasib in human plasma;Biomedical Chromatography;2024-08-13

3. A joint model of longitudinal pharmacokinetic and time-to-event data to study exposure–response relationships: a proof-of-concept study with alectinib;Cancer Chemotherapy and Pharmacology;2024-07-11

4. Reasons for non-feasibility of therapeutic drug monitoring of oral targeted therapies in oncology – an analysis of the closed cohorts of a multicentre prospective study;British Journal of Cancer;2024-07-06

5. Therapeutic Drug Monitoring of Oral Oncology Drugs: Finding the Right Nails;Clinical Pharmacology & Therapeutics;2024-07